No evidence that genetic variation in the myeloid-derived suppressor cell pathway influences ovarian cancer survival

LE Sucheston-Campbell; R Cannioto; AI Clay; JL Etter; KH Eng; S Liu; S Battaglia; Q Hu; J Brian Szender; A Minlikeeva; JM Joseph; P Mayor; SI Abrams; BH Segal; PK Wallace; KT Soh; E Zsiros; H Anton-Culver; EV Bandera; MW Beckmann; A Berchuck; L Bjorge; A Bruegl; IG Campbell; SP Campbell; G Chenevix-Trench; DW Cramer; AD Mieszkowska; F Dao; B Diergaarde; T Doerk; JA Doherty; A Du Bois; D Eccles; SA Engelholm; PA Fasching; SA Gayther; A Gentry-Maharaj; RM Glasspool; MT Goodman; J Gronwald; P Harter; A Hein; F Heitz; P Hillemmanns; C Høgdall; EVS Høgdall; T Huzarski; A Jensen; SE Johnatty; A Jung; BY Karlan; R Klapdor; T Kluz; B Konopka; SK Kjer; J Kupryjanczyk; D Lambrechts; J Lester; J Lubinski; DA Levine; L Lundvall; V McGuire; IA McNeish; U Menon; F Modugno; RB Ness; S Orsulic; J Paul; CL Pearce; T Pejovic; P Pharoah; SJ Ramus; J Rothstein; MA Rossing; M Rubner; JM Schildkraut; B Schmalfeldt; I Schwaab; N Siddiqui; W Sieh; P Sobiczewski; H Song; KL Terry; E Van Nieuwenhuysen; A Vanderstichele; I Vergote; CS Walsh; PM Webb; N Wentzensen; AS Whittemore; AH Wu; A Ziogas; K Odunsi; J Chang-Claude; EL Goode; KB Moysich

Journal article

No evidence that genetic variation in the myeloid-derived suppressor cell pathway influences ovarian cancer survival

LE Sucheston-Campbell, R Cannioto, AI Clay, JL Etter, KH Eng, S Liu, S Battaglia, Q Hu, J Brian Szender, A Minlikeeva, JM Joseph, P Mayor, SI Abrams, BH Segal, PK Wallace, KT Soh, E Zsiros, H Anton-Culver, EV Bandera, MW Beckmann Show all

Cancer Epidemiology Biomarkers and Prevention | AMER ASSOC CANCER RESEARCH | Published : 2017

DOI: 10.1158/1055-9965.EPI-16-0631

Abstract

Background: The precise mechanism by which the immune system is adversely affected in cancer patients remains poorly understood, but the accumulation of immunosuppressive/protumorigenic myeloid-derived suppressor cells (MDSCs) is thought to be a prominent mechanism contributing to immunologic tolerance of malignant cells in epithelial ovarian cancer (EOC). To this end, we hypothesized genetic variation in MDSC pathway genes would be associated with survival after EOC diagnoses. Methods: We measured the hazard of death due to EOC within 10 years of diagnosis, overall and by invasive subtype, attributable to SNPs in 24 genes relevant in the MDSC pathway in 10,751 women diagnosed with invasive ..

View full abstract

University of Melbourne Researchers

Ian Campbell Author

Related Projects (1)

Molecular Epidemiology of Ovarian Cancer: The Australian Ovarian Cancer Study National Clinical Follow-Up Core

Ovarian cancer is the seventh most common cancer in Australian women and fifth most common cause of cancer death, with approximately 1200 ne..

Grants

Awarded by National Cancer Institute

Funding Acknowledgements

The Ovarian Cancer Association Consortium is supported by a grant from the Ovarian Cancer Research Fund.r This study used shared resources supported by RPCI's Cancer Center Support grant from the NCI (P30CA016056) and was also supported by the NCI Ovarian SPORE grant P50CA159981 and Roswell Park Alliance Foundation.r L.E. Sucheston-Campbell is supported by P50CA159981 and Roswell Park Alliance Foundation.r K.B. Moysich is supported by P50CA159981 and Roswell Park Alliance Foundation, NIH/NCIR01CA095023, and NIH/NCIR01CA126841.r S.I. Abrams was supported by R01CA140622.r B.H. Segal was supported by R01CA188900.r P.K. Wallace and this work was supported by Roswell Park Cancer Institute Ovarian Spore (1P50CA159981-01A1).r J.B. Szender was supported by 5T32CA108456.r Albina Minlikeeva was supported by Interdisciplinary Training Grant in Cancer Epidemiology (R25CA113951).r AUS (G. Chenevix-Trench and P.M. Webb): U.S. Army Medical Research and Materiel Command (DAMD17-01-1-0729), National Health & Medical Research Council of Australia (199600 and 400281), Cancer Councils of New South Wales, Victoria, Queensland, South Australia, and Tasmania and Cancer Foundation of Western Australia (under Multi-State Applications 191, 211, and 182).r BAV (P.A. Fasching): ELAN Funds of the University of Erlangen-Nuremberg. BEL (D. Lambrechts): Nationaal Kankerplan.r DOV (M.A. Rossing): NIH (R01-CA112523 and R01-CA87538).r GER (J. Chang-Claude): German Federal Ministry of Education and Research, Programme of Clinical Biomedical Research (01 GB 9401), and the German Cancer Research Center (DKFZ).r HAW (M. Goodman): NIH (R01-CA58598, N01-CN-55424, and N01-PC67001).r HOP (F. Modugno, K. Moysich, and R. Ness): DOD (DAMD17-02-1-0669) and NCI (K07-CA080668, R01-CA95023, and P50-CA159981); NIH/National Center for Research Resources/General Clinical Research Center grant MO1-RR000056; R01-CA126841.r LAX (B.Y. Karlan): American Cancer Society Early Detection Professorship (SIOP-06-258-01-COUN) and the National Center for Advancing Translational Sciences (NCATS), grant UL1TR000124.r MAL (S.K. KjAEr): Funding for this study was provided by research grant R01CA61107 from the NCI, research grant 94 222 52 from the Danish Cancer Society, Copenhagen, Denmark, and the Mermaid I project.r MAY (E.L. Goode): NIH (R01-CA122443, P30-CA15083, and P50-CA136393), Mayo Foundation, Minnesota Ovarian Cancer Alliance, and Fred C. and Katherine B. Andersen Foundation.r NCO (J. Schildkraut and A. Berchuck): NIH (R01-CA76016) and the Department of Defense (DAMD17-02-1-0666).r NEC (D. Cramer and K. Terry): NIH (R01-CA54419 and P50-CA105009) and Department of Defense (W81XWH-10-1-02802).r NJO (E.V. Bandera): NCI (NIH-K07 CA095666, NIH-K22-CA138563, and P30-CA072720) and the Cancer Institute of New Jersey.r NOR (L. Bjorge): Helse Vest, The Norwegian Cancer Society, and The Research Council of Norway.r ORE (T. Pejovic): OHSU Foundation.r POC (J. Gronwald): Pomeranian Medical University.r POL (N. Wentzensen): Intramural Research Program of the NCI.r PVD (E. Hogdall and C. Hogdall): Herlev Hospitals Forskningsrad, Direktor Jacob Madsens og Hustru Olga Madsens fond, Arvid Nilssons fond, Gangsted fonden, Herlev Hospitals Forskningsrad, and Danish Cancer Society.r RMH (P. Pharoah): Cancer Research UK (no grant number is available) and Royal Marsden Hospital.r SEA (P. Pharoah): Cancer Research UK (C490/A10119 and C490/A10124) and UK National Institute for Health Research Biomedical Research Centres at the University of Cambridge.r SRO (S. Banerjee, J. Paul, N. Siddiqui, R. Glasspool, and I. McNeish): Cancer Research UK (C536/A13086 and C536/A6689) and Imperial Experimental Cancer Research Centre (C1312/A15589).r STA (A.S. Whittemore and W. Sieh): NIH (U01-CA71966, R01-CA16056, K07-CA143047, and U01-CA69417) for recruitment of controls by the Cancer Prevention Institute of California.r UCI (H. Anton-Culver): NIH (R01-CA058860) and the Lon V Smith Foundation grant LVS-39420.r UKO (U Menon, A Gentry-Maharaj, and S. Gayther): The UKOPS study was funded by The Eve Appeal (The Oak Foundation) and supported by the National Institute for Health Research University College London Hospitals Biomedical Research Centre.r UKR (P. Pharaoh): Cancer Research UK (C490/A6187) and UK National Institute for Health Research Biomedical Research Centres at the University of Cambridge.r USC (C. L. Pearce): P01CA17054, P30CA14089, R01CA61132, N01PC67010, R03CA113148, R03CA115195, N01CN025403, and California Cancer Research Program (00-01389V-20170, 2II0200).r WOC (J. Kupryjanczyk): National Science Centren (N N301 5645 40) The Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland.